NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

被引：0
|
作者：
Mao, Lili
Si, Lu
Dai, Jie
Bai, Xue
Li, Caili
Wei, Xiaoting
Cui, Chuanliang
Chi, Zhihong
Sheng, Xinan
Tang, Bixia
Lian, Bin
Wang, Xuan
Yan, Xieqiao
Zhou, Li
Kong, Yan
Wu, Xiaowen
Li, Siming
Li, Juan
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Melanoma & Sarcoma, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma
    Mao, L.
    Bai, X.
    Wei, X.
    Dai, J.
    Cui, C-L.
    Chi, Z.
    Sheng, X.
    Lian, B.
    Wang, X.
    Bixia, T.
    Si, L.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S951 - S951
  • [2] Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update
    Mao, Lili
    Dai, Jie
    Bai, Xue
    Kong, Yan
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Juan
    Li, Caili
    Wu, Xiaowen
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.
    Gonzalez, Maria
    Menzies, Alexander M.
    Pennington, Thomas
    Saw, Robyn P. M.
    Spillane, Andrew J.
    Stretch, Jonathan
    Shannon, Kerwin Frank
    Ch'ng, Sydney
    Nieweg, Omgo E.
    Rojas, Maria Cruzado
    Osorio, Monica
    Rawson, Robert, V
    Ferguson, Peter M.
    Rizos, Helen
    Lo, Serigne
    Scolyer, Richard A.
    Long, Georgina, V
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [5] NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
    Long, G. V.
    Spillane, A. J.
    Pennington, T. E.
    Shannon, K. F.
    Stretch, J.
    Gonzalez, M.
    Saw, R. P. M.
    Lo, S. N.
    Scolyer, R. A.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S906 - S907
  • [6] S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.
    Patel, Sapna Pradyuman
    Othus, Megan
    Moon, James
    Tetzlaff, Michael T.
    Buchbinder, Elizabeth Iannotti
    Sondak, Vernon K.
    Lowe, Michael C.
    Campos, Danae
    Sharon, Elad
    Korde, Larissa A.
    Carson, William Edgar
    Ribas, Antoni
    Grossmann, Kenneth F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.
    Cui, Chuanliang
    Wang, Xuan
    Lian, Bin
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Mao, Lili
    Bai, Xue
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
    Lowe, Michael C.
    Olson, Brian
    Martinez, Anthony
    Hammons, Jacklyn
    Delman, Keith A.
    Yushak, Melinda Lynne
    Allor, Melanie
    Reilly, Christine A.
    Mallow, Crystal L.
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Lesinski, Gregory B.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
    Shah, G. D.
    Socci, N. D.
    Gold, J. S.
    Wolchok, J. D.
    Carvajal, R. D.
    Panageas, K. S.
    Viale, A.
    Brady, M. S.
    Coit, D. G.
    Chapman, P. B.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1718 - 1722
  • [10] ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.
    Johnson, Melissa Lynne
    Gonzalez, Rene
    Opyrchal, Mateusz
    Gabrilovich, Dmitry
    Ordentlich, Peter
    Brouwer, Susan
    Sankoh, Serap
    Schmidt, Emmett V.
    Meyers, Michael L.
    Agarwala, Sanjiv S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345